Skip to Content
Merck
All Photos(1)

Documents

QBD10275

Sigma-Aldrich

MAL-dPEG®8-acid

>95% (HPLC)

Synonym(s):

Carboxy-PEG-maleimide, Carboxy-PEG8-maleimide, MAL-PEG400-acid, MAL-PEG8-COOH, MAL-PEG8-acid

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C26H44N2O13
Molecular Weight:
592.63
MDL number:
UNSPSC Code:
12352106
NACRES:
NA.22

Assay

>95% (HPLC)

form

solid or viscous liquid

reaction suitability

reaction type: Pegylations

polymer architecture

shape: linear
functionality: heterobifunctional

shipped in

ambient

storage temp.

−20°C

Features and Benefits

MAL-dPEG8-acid is a monodisperse crosslinker that joins sulfhydryl groups to free amines through a single molecular weight polyethylene glycol (PEG) chain of discrete length. The linker is 34 atoms and 38.8 Å long. The maleimidopropyl moiety reacts with sulfhydryl groups via a Michael addition reaction. The propionic acid terminus of the molecule reacts directly with free amines using EDC or another carbodiimide to form amide bonds. Alternatively, activation of the propionic acid group with N-hydroxysuccinimide (NHS), 2,3,5,6-tetrafluorophenol (TFP), or some other acylating agent permits amide bond formation under mild, controlled conditions.

Legal Information

Products Protected under U.S. Patent #s 7,888,536 & 8,637,711 and European Patent #s 1,594,440 & 2,750,681
dPEG is a registered trademark of Quanta BioDesign

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sara Movassaghian et al.
Molecular pharmaceutics, 13(8), 2605-2621 (2016-05-26)
Basal-like breast cancer (BLBC) accounts for the most aggressive types of breast cancer, marked by high rates of relapse and poor prognoses and with no effective clinical therapy yet. Therefore, investigation of new targets and treatment strategies is more than

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service